Showing 31-40 of 115 results for "".
PsO Treatment Guidelines: The Role of Systemic Medications
https://practicaldermatology.com/topics/psoriasis/pso-treatment-guidelines-the-role-of-systemic-medications/19649/Biologics and new JAK inhibitors play an important role in managing psoriasis. Neal Bhatia, MD offers his thoughts on when and why these treatments should be considered.Advanced Systemic Therapeutics
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-systemic-therapeutics/18755/By Seemal R. Desai, MD and Neal Bhatia, MD, FAADFrom updates in infectious disease to hormonal therapies, and off-label uses of biologics, the key to successful treatment is matching mechanisms to disease states. Dr. Bhatia explains.Defining the Physician-Patient Relationship
https://practicaldermatology.com/topics/practice-management/defining-the-physician-patient-relationship/18928/In this edition of Derm Insider, Allan Wirtzer, MD and Cliff Lober, MD, JD talk to host Neal Bhatia, MD about the importance of defining the physician-patient relationship, determining when the relationship is established, and understanding the legal implications that come with that fiduciary or heiDerm Insider: Ethics and Industry: How to Manage Relationships with Pharma
https://practicaldermatology.com/topics/practice-management/derm-insider-ethics-and-industry-how-to-manage-relationships-with-pharma/19029/In this edition, host Neal Bhatia, MD and guests Tom Prunty and James Q. Del Rosso, DO tackle the ethics of industry relationships. They discuss the nuances and challenges of physicians fostering appropriate relationships with pharmaceutical manufacturers amid an increasingly stringent regulatory laDermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Conversations in Acne, Part 2
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-2/19871/From isotretinoin to antibiotics—including next generation tetracyclines—the experts talk about key considerations for optimal outcomes, including the impact of diet. They also discuss management of trunk acne and strategies to reduce the risk for bacterial resistance. Host Neal Bhatia, MD leads thePros and Cons of DTC Advertising
https://practicaldermatology.com/topics/practice-management/pros-and-cons-of-dtc-advertising/18569/Hilary Baldwin, MD and James Q. Del Rosso, DO sit down with Derm Insider Host Neal Bhatia, MD to weigh the pros and cons of direct-to-consumer advertising on patients. They agree that if done well and with a primary focus on disease state rather than a specific drug, these ads can encourage patientsAK Pearls: Managing Treatment Reactions
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-pearls-managing-treatment-reactions/18741/Dr. Bhatia shares pearls for managing side effects and reactions to actinic keratosis treatment drugs. There are many adjunctive therapies to counter these reactions from emollients to barrier repair cream to time and some TLC for patients.Why Assessing Vitiligo Activity is Critical for Limiting Spread
https://practicaldermatology.com/conferences/maui-derm-2024/why-assessing-vitiligo-activity-is-critical-for-limiting-spread/20248/Chief Medical Editor Neal Bhatia, MD talks with “Mr. Vitiligo Himself,” John E. Harris, MD, PhD about the importance of determining whether vitiligo patients are active or stable in order to “shut off” spreading as soon as possible.New Drugs & Therapies 2024 Recap
https://practicaldermatology.com/topics/psoriasis/new-drugs-therapies-2024-recap/20240/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, and Baylor College dermatology professor, Ted Rosen, MD, review the highlights of their Maui Derm opening presentation. From Cabtreo’s triple combination, one-tube acne treatment to the two new, different-yet-effective treatments for mollus